Fed’s Powell opens door to potential rate cuts at Jackson Hole
FMC Corp (NYSE:FMC) President Ronaldo Pereira recently made significant acquisitions of the company’s stock, according to a filing with the Securities and Exchange Commission. The purchases come as FMC shares have declined over 40% in the past six months, with the stock currently trading at $38.96. According to InvestingPro analysis, FMC appears undervalued based on its Fair Value assessment. On March 4, Pereira purchased 5,600 shares of FMC common stock at an average price of $35.775 per share, totaling approximately $200,340. This transaction increased his direct ownership to 48,837.369 shares.
Additionally, Pereira acquired 2,594 shares through a thrift plan at a price of $35.66 per share, valued at $92,502. Following these transactions, Pereira’s total indirect ownership stands at 8,164.234 shares.
In other recent news, FMC Corp has reported mixed earnings results, with its fourth-quarter earnings per share (EPS) surpassing analyst expectations by $0.19. However, the company’s forecast for 2025 indicates a lower EPS range of $3.26 to $3.70, falling short of the projected $4.36. In terms of sales, FMC Corp anticipates 2025 figures to be between $4.15 and $4.35 billion, with earnings before interest, taxes, depreciation, and amortization (EBITDA) expected to range from $870 to $950 million. The company projects significant growth by 2027, with sales and EBITDA expected to rise to $5.2 billion and $1.2 billion, respectively.
In other developments, FMC Corp has extended its $2.0 billion revolving credit facility by one year, now set to terminate in June 2028. Analyst firms have also adjusted their ratings and price targets for FMC Corp. Redburn-Atlantic downgraded the stock from Buy to Neutral, setting a price target of $49.00 due to concerns over expiring patents and potential competition from generics. Citi maintained a Neutral rating with a $38.00 price target, while Jefferies lowered its price target from $61.00 to $49.00 but upheld a Buy rating. Meanwhile, KeyBanc Capital Markets reduced its price target from $55.00 to $51.00, maintaining an Overweight rating, citing challenges related to FMC’s diamides franchise transitioning off-patent.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.